Health Care Market News Sponsored Technology NervGen: Are amazing human trial results leaking out? NervGen Pharma Corp. (TSXV:NGEN) hopes to commercialize the world’s first ever FDA-approved drug to treat spinal cord injuries. Knox Henderson7 mins02 July 2024 08:00 (EDT)
Health Care Market News Sponsored Technology Can NervGen keep a lid on explosive news? Is NervGen Pharma Corp. (TSXV:NGEN; OTCQX:NGENF) struggling to keep a lid on explosively transformative news? It looks that way. Knox Henderson6 mins20 March 2024 07:00 (EDT)
Contributors & Collaborations Health Care Market News Is this stunning ‘evidence’ that NervGen has the goods? This could be the signal that tiny NervGen Pharma (TSX-V:NGEN) is destined to be one of the top performing biotech startup stocks this year. Knox Henderson7 mins01 February 2024 07:00 (EDT)
